With for firm's corporate headquarters in Rhode Island but having research facilities in Cambridge MA, Bolden Therapeutics is a biotechnology company developing first-in-class therapeutics to treat central nervous system diseases such as Alzheimers disease and ischemic stroke. The firm is structured around the scientific founders having determined a key molecular pathway to promote the birth of new neurons (neurogenesis) in the adult brain. In a proprietary mouse model Bolden has established proof-of-concept of this approach to increase neurogenesis and enhance hippocampal-dependent memory believed to play an important role in learning and memory. Diminished neurogenesis can contribute to cognitive dysfunction and memory impairment, and this phenomenon is observed in multiple neurodegenerative diseases and neurological conditions. In addition, neurogenesis has been implicated as important for functional recovery following traumatic brain injury and ischemic stroke.There are potentially various potential clinical applications for neurogenesis-promoting therapies around which the firm is organized includiing - but not limited to - Alzheimers disease and related dementias, ischemic stroke, treatment-resistant depression, Huntingtons disease, Parkinsons disease, traumatic brain injury, and cognitive impairment following chemotherapy.